Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Healthcare Drug Manufacturers - Major Cannabis
Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Aphria Inc.
Bullboard Posts
User Avatar Image
(41)
•••
Post by TheFixer5on Jan 17, 2020 10:23am
133 Views
Post# 30564800

Best go hide potman/methodman

Best go hide potman/methodman

Theralase Wins Precedent-Setting Lawsuit Against Anonymous Individuals for Posting Defamatory Comments Online

Thursday, January 16, 2020 4:15 PM

Theralase, as a clinical stage pharmaceutical company, is now able to turn its full attention to the completion of its pivotal Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study, and if proven successful, the commercialization of the Company's next-generation anti-cancer technology for the benefit of all
stakeholders."

https://www.accesswire.com/573350/Theralase-Wins-Precedent-Setting-Lawsuit-Against-Anonymous-Individuals-for-Posting-Defamatory-Comments-Online
 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities